Corrections log

Recent corrections

Dated record of factual corrections and material updates to this page. We publish corrections rather than silently edit. Trust signal, not legal compliance.

1. 2026-09-15· 9 research pages

   Rewrote the “Key findings” summaries on 9 research pages so every point matches the article and its cited sources. The sleep-deprived cities summary had presented another publisher’s ranking (Norfolk first) as our own; the ranking the article cites puts Honolulu first (42.3%). The supplement-spending summary gave state figures for Maryland, Colorado and Massachusetts that no cited source supports; the BLS does not publish supplement spending by state, and the summary now says so. We also replaced figures we could not trace to the cited data: a hair-loss market forecast, working-adult sleep trends, a vitamin D threshold, a teen screen-time breakdown and a Nevada uninsured rate.

2. 2026-09-15· 25 condition pages

   Checked the key facts on 25 condition pages against primary sources and corrected the ones that did not hold up: prediabetes prevalence updated to the CDC’s current 115.2 million U.S. adults; Opzelura’s eczema approval now reads ages 2 and older (not 12); antidepressants usually take four to eight weeks (not two to six); sleep-apnea trial results corrected to 42.2% and 50.2% (NEJM); NAFLD now states that about 10% or more weight loss is generally needed to improve fibrosis; the ADHD figure updated to 11.7% of U.S. children. Contested figures (NAFLD prevalence, the depression sex ratio and heritability, testosterone decline with age, adult acne rates) now give ranges or name their source, and two guideline citations were reworded to match what the guidelines say. Every condition page now lists its sources.

3. 2026-09-15· 22 product reviews and every page that shows their prices

   Re-verified prices for 22 weight-loss and GLP-1 products against their official pricing pages. Wegovy, Ozempic, Zepbound and Mounjaro showed list prices ($997–$1,349 a month) instead of the manufacturers’ self-pay prices ($299–$499 a month for the starting doses). Form Health, Henry Meds, Mochi, PlushCare, WeightWatchers Med+, Ro and Calibrate showed outdated, introductory or mistyped prices. Each verified price now shows the date it was checked and links to its source page.

4. 2026-09-15· Rybelsus and Hims compounded semaglutide reviews

   Novo Nordisk is replacing Rybelsus with the Ozempic pill, and Hims no longer lists compounded semaglutide on its weight-loss page. Both reviews now open with a status note, and prices we could no longer verify were removed.

5. 2026-09-15· Amazon Pharmacy review

   The Amazon Pharmacy review now states that RxPass ($5 a month) covers 50+ generics only and does not include GLP-1s or other brand-name weight-loss drugs.

6. 2026-09-15· Sequence and Ro Body reviews

   Merged duplicate reviews: Sequence was folded into WW Clinic, so its review now redirects to WeightWatchers Med+; a second Ro Body review now redirects to the main one.

7. 2026-09-15· Henry Meds oral semaglutide, Ivím Health, Rybelsus, Everlywell and Talkiatry reviews

   Replaced two provider pricing links that returned “page not found” and removed three source links that no longer resolve.

8. 2026-09-15· Comparison and best-of pages

   Comparison pages and best-of rankings now list the primary sources (FDA labeling, peer-reviewed studies, official pricing pages) behind the reviews they summarize. Previously these pages showed no sources.

9. 2026-09-14· 118 comparison pages

   Comparison pages labeled products with no active ingredient on file — including therapy services and supplements — as a "GLP-1 receptor agonist". The label now appears only when a product has a real active ingredient.

10. 2026-09-14· All review, comparison and listing pages

    Products without a licensed photo were shown with drawn packaging — an injection pen or pill bottle printed with "GLP-1" and a dose — even when the product was a therapy app or a supplement. The drawings implied facts that were not true; products now show a neutral brand monogram instead.